Earnings Summary

Ultragenyx Pharmaceutical Inc.’s revenue jumped 23.27% since last year same period to $127.39Mn in the Q4 2023. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 29.92% jump in its revenue since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit jumped 18.86% since last year same period to $-123.19Mn in the Q4 2023. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 22.84% jump in its net profits since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit margin jumped 34.18% since last year same period to -96.7% in the Q4 2023. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 40.61% jump in its net profit margins since last 3-months.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.76 - a -8.64% fall from last quarter’s estimates.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at -1.76.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) jumped 29.63% since last year same period to -1.52 in the Q4 2023. This indicates that the Ultragenyx Pharmaceutical Inc. has generated 29.63% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ultragenyx Pharmaceutical Inc.’s return on assets (ROA) stands at -0.23.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ultragenyx Pharmaceutical Inc.’s return on equity (ROE) stands at -1.93.